328 Results
Neuroimaging
The application of neuroimaging technology in psychiatric research has revolutionized clinical neuroscience perspectives on the pathophysiology of the major psychiatric disorders. Research using a variety of types of neuroimaging techniques has shown that these conditions are associated with abnormalities of brain function, structure and receptor pharmacology. These data also corroborate the conclusions reached from genetic, endocrine, and clinical pharmacology research involving these disorders
Opposition to Cannabis as Medicine
The medical use of cannabis has received considerable attention as several states have voted to remove civil and criminal penalties for patients with qualifying conditions. Yet, on a national level, cannabis remains a schedule I substance under the Controlled Substances Act (CSA), the most restrictive schedule enforced by the Drug Enforcement Administration (DEA) (1). The Food and Drug Administration (FDA), responsible for approving treatments after appropriate and rigorous study, has not approv
Position Statement on Discrimination Against Transgender and Gender Non-Conforming Individuals
Position Statement on Discrimination Against Transgender and Gender Non-Conforming Individuals
Position Statement on Orchiectomy or Treatment with Anti-Androgen Medications as a Condition of Release from Incarceration
Position Statement on Orchiectomy or Treatment with Anti-Androgen Medications as a Condition of Release from Incarceration
Decisional Capacity Determinations in Consultation-Liaison Psychiatry: A Guide for the General Psychiatrist
Consultation-Liaison Psychiatrists are experienced in responding to requests from medical services for the determination of decisional capacity (DC). General psychiatrists are occasionally called upon to perform decisional capacity determinations, especially when functioning in a consultation-liaison role. Some may not have extensive prior or current experience in decisional capacity determinations. In recent years, there has been a significant amount of clinical research literature on DC, part
Position Statement on The Mental Health Impact on People Displaced by Climate Change
Position Statement on The Mental Health Impact on People Displaced by Climate Change
AACAP Position Statement on Mental health, Children and Disasters
AACAP Position Statement on Mental health, Children and Disasters
Consensus statement on "Managing the risks of repetitive transcranial stimulation"
In response to the changing managed care environment, the APA Committee on Managed Care established a subcommittee to document the changes in managed care and to begin the process of thinking about alternative healthcare financing systems. The Committee undertook writing a resource document for APA members to identify and describe the changes that are occurring in the healthcare sector and to prepare them for changes that may occur so that psychiatry can be proactive in meeting these challenges
Position Statement on Banning of Pharmacy Benefit Management Policies that Require the Provision of Dangerous Quantities of Medications
Position Statement on Banning of Pharmacy Benefit Management Policies that Require the Provision of Dangerous Quantities of Medications
Non-Emergency Involuntary Medication for Mental Disorders in U.S. Jails
Psychiatrists who work in jail settings will encounter patients for whom the administration of non-emergency involuntary medication is clinically indicated for the stabilization of their serious mental illness. This resource document is intended to guide psychiatrists in decision-making about non-emergency involuntary psychiatric medication administration in U.S. jails by providing background information and highlighting issues for consideration.
Marijuana as Medicine
The medical use of marijuana has received considerable attention as several states have voted to remove civil and criminal penalties for patients with qualifying conditions. Yet, on a national level, marijuana remains a schedule I substance under the Controlled Substances Act (CSA), the most restrictive schedule enforced by the Drug Enforcement Administration (DEA) (1). The Food and Drug Administration (FDA), responsible for approving treatments after appropriate and rigorous study, addit